Kornimate/medical-research-clean huggingface dataset:
next generation x-ray imaging system

Conditions: Stroke, Acute

Summary: philips healthcare has developed a next generation allura investigational device. the intended purpose of the investigational device is to perform neurovascular imaging applications, including diagnostic, interventional and minimally invasive procedures on human patients. the goal of this study is to investigate the accuracy of the next generation allura investigational device to determine the extent and localization of ischemic stroke changes in brain tissue.


Eligibility criteria:
inclusion criteria: 1. the patient has signed and dated the informed consent form (icf) 2. age ≥ 50 years old 3. clinical and radiological signs consistent with acute stroke i. patient diagnosed with ischemic stroke of the anterior circulation and not eligible for thrombectomy. ii. patient diagnosed with ischemic stroke of the anterior circulation and subjected to thrombectomy. iii. patient diagnosed with hemorrhagic stroke. exclusion criteria: 1. pregnant or breastfeeding women. 2. previous stroke or parenchymal damage/defects in anterior circulation territories (only applicable for subjects included by criterion 3.i or 3.ii). 3. subject participates in a potentially confounding drug or device trial during the course of the study. 4. participation in the study exposes the subject to risk, as assessed at the discretion of the treating physician. 5. all subjects who meet an exclusion criteria according to national law. 6. subject or subject family member is a known philips employee.
stigma and efficacy of zhizhu kuanzhong capsules

Conditions: Functional Gastrointestinal Disorders; Dyspepsia; Psychosomatic Disorder

Summary: antidepressants are effective in patients with functional dyspepsia (fd), however, the stigma related with fd and antidepressants could affect treatment adherence and efficacy. zhi zhu kuan zhong capsules (zzkz), a traditional chinese medicine fomula, showed therapeutic potential for fd. the study was designed to investigate whether zzkz could alleviate stigma in fd and obtain identical effects in patients with refractory fd.

patients with dyspepsia have poor quality of life and emotional distress. the pathophysiology of fd is complex and multifactorial, including factors related to central nervous system and peripheral sensory system. abundant drugs have been trialed to treat fd patients, but the treatment options remain limited and far from optimal. antidepressants were beneficial in the treatment of fd. but the antidepressant prescriptions often aggravate the stigma of patients with fd, hinder doctor-patient communication, and reduce treatment compliance. some patients with strong stigmatized feelings towards antidepressants refused to take the medications, and stigma related with antidepressants could ultimately affect the efficacy of fd. zhizhu kuanzhong capsules (zzkz), a commonly used traditional chinese medicine (tcm) formula, had shown effectiveness in relieving dyspeptic symptoms. it has a long culture and history in promoting the function of brain and gi tract in whole, which is widely accepted by populations who were familiar with tcm. the study was designed to observe whether zzkz could alleviate stigma of patients and obtain identical effects in patients with fd, therefore provide a new insight in the treatment of fd.

Eligibility criteria:
inclusion criteria: * the inclusion criteria includes: * 18-70 years old; * education level higher than middle school; * met the rome iv criteria for fd; * absence of abnormalities on physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), and abdominal imaging and gi endoscopy within 6 months; * absence of helicobacter pylori infection; * signed written informed consent for participation in the study. exclusion criteria: * the exclusion criteria includes: * evidence of organic digestive diseases; * diabetes, cancer and other diseases might affect gi function; * pregnancy, lactation or breastfeeding; * a history of allergic reaction to any of the drugs used in the study; * participation in other clinical trials in the previous 3 months.
finding new targets by proteomic approaches (innovrt1)

Conditions: ATRT

Summary: the investigators aim to explore the inter tumor heterogeneity by a proteomic approach of a wide series of rhabdoid tumors, from both intra and extra cranial origins.

context: rhaboid tumors (rt) are aggressive cancers of young infants, exposed to the toxicity of heavy treatments often ineffective, which justifies the need to identify new treatment strategies. these tumors are characterized by the biallelic alteration of smarcb1 gene, encoding one of the subunits of the swi/snf complex, a chromatin remodeler. these mutations are the only ones found in these very stable cancers, which offers few therapeutic targets that can be identified by genomic techniques. they are morphologically undifferentiated and pluriphenotypic, suggesting the existence of a cellular diversity still poorly described. to advance on these questions, the investigators' laboratory has developed a model of genetically engineered mouse model spontaneously developing rt, biologically very similar to their human counterparts. objectives and methods: the investigators' project aims to describe the proteomic and phosphoproteomic signatures of these tumors, so far described at the genome and transcriptome level; an integration of these pangenomic / pan-proteomic studies will reveal the most relevant features to target. the investigators will fully characterize the proteomic and phosphoproteomic landscape using mass spectrometry on a cohort of clinically, radiologically and histopathologically annoted atrt, for which methylome and rnaseq profiling will also be done. the investigators will describe the proteomic features of each molecularly defined subgroups, and aim to correlate rnaseq changes with proteomic features. patients will be included if they or their legal representative have given a consent to such a study, and if frozen material is stored at necker hospital. expected results: this analysis helps to identify how to articulate several innovative therapeutic approaches, taking into account both the diversity of the cells to be treated, and the real targets, proteins, to inhibit or restore.

Eligibility criteria:
inclusion criteria: * aged 0-17 years old * rhabdoid tumor, treated in oncology departments in ile de france * frozen samples collected in usual care * parents' agreement for samples collection in usual care exclusion criteria * unconfirmed diagnosis of rhabdoid tumor with molecular analyses samples * paraffin embedded tissues

Keywords: smarcb1 atrt brain tumors proteomic multi-omics
prospective study evaluating a novel mobile app based preventive behavioral intervention for perinatal mood disorders

Conditions: Perinatal Depression; Perinatal Anxiety

Summary: the primary aim of the study is to investigate whether a novel mobile app-based behavioral intervention in pregnant women can: (1) prevent and/or decrease the incidence of perinatal mood disorders (2) decrease the severity and/or duration of perinatal mood disorders in affected participants (3) increase access of pregnant women to behavioral intervention and support tools (4) increase the satisfaction of pregnant women with their prenatal care.

perinatal depression is an episode of major or minor depression that occurs during pregnancy or in the 12 months after birth; it affects about 10% of new mothers. postpartum depression accounts for 12.5% of psychologically related hospitalizations among women. in 2019, the united states preventive services task force (uspstf) recommended screening pregnant women to identify those at risk for perinatal depression and refer them for counseling. the uspstf recommendation is based on growing literature indicating that counseling women at risk for perinatal depression reduce the risk of having an episode of major depression by 40%. supporting that, multiple studies have shown that cognitive-behavioral intervention and mental health care adjuvant therapy can effectively improve the condition of patients with postpartum depression. finally, access to care has also been shown to be an important factor in determining the success of any intervention. women across high and low-risk groups often have barriers to treatment due to stigma, shame, and fear to disclose symptoms to health providers in this research, the investigators aim to investigate whether a novel mobile app-based behavioral intervention can meaningfully increase access and demonstrate a beneficial effect in preventing anxiety and depression in the postpartum period. furthermore and adding to the existing literature in post-partum depression, this study aims to investigate the role of "positive intelligence", an integrative positive cognitive behavioral therapy, as a tool in the prevention and treatment of perinatal mood disorders.

Eligibility criteria:
inclusion criteria: * able to read and speak english * have a low-risk singleton pregnancy with more than 24 weeks of gestation * have smartphone with internet access * failure to meet criteria for a diagnosis of mdd in the last two months exclusion criteria: * physical or mental disorders which would interfere with their ability to participate in the study * high-risk pregnancy * give birth to a newborn at still-birth or a newborn with congenital anomalies and/or medical complications that require special care in hospital * infant has a birth weight lower than 2,500 grams * infant has a 5-minute apgar score lower than 7
a pilot study to obtain preliminary information regarding the efficacy and safety of the combination of immune globulin and ganciclovir as compared to ganciclovir alone in the treatment of sight-threatening cmv retinitis in patients with aids

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: to evaluate whether immune globulin and ganciclovir (dhpg) results in faster initial response as compared to dhpg alone. to evaluate whether immune globulin and dhpg gives longer duration of remission than dhpg alone (i.e. 16 weeks). to evaluate the toxicities of the combination of dhpg and immune globulin as compared to those of dhpg alone. to evaluate if there is a difference between the two groups in regard to survival, immune functions, and cmv viremia and viruria.


Eligibility criteria:
inclusion criteria patients must have the following: * first episode of sight-threatening cmv retinitis. * at least one pending culture for cmv from the blood or urine prior to entry. * life expectancy \> 6 months. * karnofsky performance = or \> 60. * ability to understand the nature of the study, to comply with study requirements, and to sign informed consent. exclusion criteria co-existing condition: patients with the following conditions are excluded: * known selective iga deficiency or antibodies against iga. * history of previous episodes of sight-threatening cmv retinitis. patients with the following are excluded: * previous episode of sight-threatening cmv retinitis. * concomitant treatment with other investigational agents except ddi or ddc. * life expectancy \< 6 months. * continued alcohol or drug abuse. * known selective iga deficiency and known to have antibodies against iga. * karnofsky performance \<60. other investigational agents except ddi or ddc. ddi ddc

Keywords: retinitis gamma-globulins ganciclovir drug therapy, combination cytomegalovirus infections acquired immunodeficiency syndrome immunization, passive
validity and inter-rater reliability for early recognition of spasticity using the decision tree tool

Conditions: Post-stroke Spasticity

Summary: the aim of this study is to investigate the validity and inter-rater reliability for early recognition of spasticity by nurses and physiotherapists using the decision tree tool.

the spastic movement disorder (smd) decision tree was designed as a tool to aid nurses, therapists and other healthcare professions recognize potential signs of disabling spasticity in the upper limb of post-stroke patients. the present study assesses validity and inter-rater reliability of the smd decision tree comparing nurses and therapists with gold-standard procedure performed by rehabilitation doctors. agreement was tested for "referral to specialist indicated" and "no referral to specialist indicated".

Eligibility criteria:
inclusion criteria: * participants with a first sub-acute and chronic infarction of the middle cerebral artery / basal ganglia hemorrhage longer than four weeks after the event * between 18-80 years old * preserved insight and judgment capacity * adequate language and task comprehension, attention span for 15 minutes exclusion criteria: * participants with other neurological disorders * participants who received bont-a treatment \< 3 months before inclusion * reduced vigilance and attention span (less than 15 minutes) * participants with adult representation * participants with severe language impairment / impairment of movement and action sequences
biological, prospective study evaluating the dosage of plasma cytokines including the flt3 ligand and il6 of patients treated with non-intensive chemotherapy

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia

Summary: there are 2 possible treatments for the treatment of acute myelogenous leukemia (aml), high-risk myelodysplastic syndromes (hr-mds) or chronic myelomonocytic leukemia (cmml): intensive curative chemotherapy , and for over-aged or co-morbid patients , non-intensive palliative chemotherapy with a hypomethylating agent (azacytidine) associated or not with venetoclax. pro-inflammatory cytokines and in particular il-6 (interleukin 6) seem to play a key role in the chemoresistance of solid cancers and aml : it would be associated with a poor prognosis of aml , would promote the proliferation of leukemic blasts , and would promote the progression of mds to aml . in aml treated with intensive chemotherapy, researchers demonstrated that a particular kinetic profile of the flt3 ligand and il6 at day 22 could very significantly predict the survival of patients with aml . it therefore seems interesting to study the plasma cytokine profiles in patients with aml, hr-mds or cmml treated non-intensively, and to see if researchers observe the same prognostic correlation as during intensive chemotherapy.

patients will be divided into 2 groups treated according to a non-intensive chemotherapy : group 1 : 40 patients treated with azacytidine and venetoclax +/- another molecule according to the following schedule: * azacytidine 75 mg/m² d1 to d7 sc * venetoclax: 400 mg/day orally in 1 dose between 14 and 28 days per cycle. the cycles will be 28 days long and will be carried out until relapse or death. cytokine assays will be carried out on d1, d8, d15 and d22 of each cycle for 2 cycles. group 2 : 20 patients treated with azacytidine +/- another molecule according to the following schedule: • azacytidine 75 mg/m² d1 to d7 sc the cycles will be 28 days long and will be carried out until relapse or death. the cytokine assays will be carried out on d1, d8, d15 and d22 of each cycle for 3 cycles. the duration of follow-up for a patient is 12 months from day 1 of the first cycle.

Eligibility criteria:
inclusion criteria : * age \>=18 years * aml or smd-hr or cmml in first line or in relapse receiving a hypomethylating agent +/- another molecule or a hypomethylating agent in combination with venetoclax +/- another molecule. * patient having agreed to participate in the study (information note signature) and having signed the biocollection consent exclusion criteria : * no social security or any other regime * pregnant women or patient unable to take contraception in case of fertility * breastfeeding women * minors * adults under guardianship, curators or safeguard of justice

Keywords: cytokine il 6 flt3 ligand aml cmml hr mds azacytidine
efficacy of changing to duotrav® from prior therapy

Conditions: Open-Angle Glaucoma; Ocular Hypertension; Pigment Dispersion Glaucoma

Summary: the purpose of this study was to assess the efficacy and tolerability of changing to duotrav® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having uncontrolled intraocular pressure (iop).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension, open-angle or pigment dispersion glaucoma in at least one eye. * stable iop-lowering regimen of bimatoprost 0.03%/timolol 0.5% therapy (either administered concomitantly or in a fixed combination) within 4 weeks prior to the screening visit. * iop considered to be safe (in the opinion of the investigator), in both eyes, to assure clinical stability of vision and the optic nerve throughout the study period. * iop between 19 to 35 mmhg (at any time of the day) in at least one eye (which would be designated as the study eye). * willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study. * able to follow instructions and willing and able to attend all study visits. * best corrected visual acuity of 6/60 (20/200 snellen, 1.0 logmar) or better in each eye. * sign informed consent. * other protocol-defined inclusion criteria may apply. exclusion criteria: * known medical history of allergy, hypersensitivity or poor tolerance to any component of duotrav® that is deemed clinically significant in the opinion of the principal investigator. * corneal dystrophies in either eye. * risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker. * history of severe allergic rhinitis. * a condition, which in the opinion of the principal investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject. * participation in any other investigational study within 30 days prior to the screening visit. * other protocol-defined exclusion criteria may apply.

Keywords: open-angle glaucoma ocular hypertension pigment dispersion glaucoma intraocular pressure
comprehensive analysis of hypoxia in prostate cancer: diagnostic markers and prognostic significance

Conditions: Prostate Cancer

Summary: a single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer

1. to perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers 2. to characterize expression and hypoxia/hif-responsiveness of myoglobin, cytoglobin, α-hemoglobin in prostate tumors and cell lines 3. to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancers

Eligibility criteria:
inclusion criteria: * patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the department of urology, university hospital of zurich * written informed consent exclusion criteria: * metastatic prostate cancer * contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product * severe heart or lung disease * severe liver or kidney dysfunction * severe stridor * distant metastases * concurrent treatment for other malignant disease * prior hormonal therapy or radiotherapy
azd7268 safety and tolerability study

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to prove the principle that treatment with azd7268 reduces depressive symptoms in patients with major depressive disorder (mdd) compared with placebo.


Eligibility criteria:
inclusion criteria: * provision of signed, written, and dated informed consent prior to any study specific procedures * documented primary clinical diagnosis meeting criteria from the dsm-iv, text revision (apa 2000) for any of the following: * 296.2x major depressive disorder, single episode, or * 296.3x major depressive disorder, recurrent exclusion criteria: * patients with a secondary dsm-iv axis i disorder other than gad or social anxiety disorder (as assessed by mini), provided the primary diagnosis is mdd. this diagnosis should have been made at least 6 months before enrollment * patients with a diagnosis of dsm-iv axis ii disorder which has a major impact on the patient's current psychiatric status * patients whose current episode of depression started less than 4 weeks before enrollment

Keywords: depression
adequacy of pain treatment in radiotherapy

Conditions: Cancer Pain; Analgesic Drugs

Summary: aim of the study is to evaluate adequacy of pain treatment in oncologic patients, accessing to radiotherapy unit

prescription of analgesic drugs is a basic topic in cancer patients, but undertreatment is common. the aim of the study is to analyse pain control and adequacy of antalgic treatments in patients coming to radiotherapy unit for radiation treatment.

Eligibility criteria:
inclusion criteria: - patients accessing to radiotherapy unit for radiation treatment (both palliative or with radical intent) with diagnosis of primitive or metastatic cancer; exclusion criteria: - concomitant diseases that can affect reliability of collected data